Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 6/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14277156 | 0.88 | MAPT (0.47) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL2689161 | 0.88 | MAPT (0.47) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL5638082 | 0.81 | CYP3A4 (0.42) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL1114602 | 0.79 | CYP3A4 (0.44) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL5639089 | 0.78 | DPP4 (0.40) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL5639256 | 0.76 | CYP3A4 (0.41) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL5639092 | 0.76 | HPGD (0.42) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL5639951 | 0.75 | MEN1 (0.37) | SMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL5636144 | 0.75 | TSHR (0.46) | CYP3A4TSHRTDP1MAPTAPEX1 | |
| SCHEMBL5640952 | 0.74 | MEN1 (0.36) | SMN1; SMN2MEN1KMT2AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220856-B2 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | CCR5, CXCR3, CCR2 | CYP3A4 662/4885TSHR 667/4885TDP1 3234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.